Markets

Cymabay Therapeutics (CBAY) Looks Good: Stock Up 7.2%

Cymabay Therapeutics, Inc. ( CBAY ) was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company - as the stock is now up more than 13% in the past one-month time frame.

The company has seen no estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's move higher can last.

Cymabay Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

A better-ranked stock in the same space is Dr. Reddy's Laboratories Ltd. ( RDY ) sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CYMABAY THERAPT (CBAY): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CBAY RDY

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More